ArticleCureus2025
Effect of Transarterial Chemoembolization on Health-Related Quality of Life in Patients With Hepatocellular Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stress response, complications, and postoperative recovery in patients with hepatocellular carcinoma and comorbid anxiety/depression undergoing ultrasound-guided intervention.World journal of psychiatry · 2025Article
- Determinants of Health-Related Quality of Life After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Systematic Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimWe evaluated health-related quality of life (HRQoL) in patients with hepatocellular carcinoma (HCC) before and after transarterial chemoembolization (TACE) and the clinical and biochemical factors that can predict changes in quality of life (QoL).
methodsA total of 45 patients were enrolled in the study and followed up for a period of three months. HRQoL was assessed using an HCC-specific questionnaire at baseline, two weeks, and three months. Tumor response was evaluated at six weeks using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.
resultsBefore TACE, the aspects of the functional scales most significantly impacted were global health status (53.1±29.3%) and physical functioning (68.7±20.7%). The commonly reported symptoms and their corresponding QoL scores were as follows: fatigue (46.4±32.5%), followed by insomnia (32.6±36.6%) and abdominal pain (32.2±30.8%). Financial constraints (63.0±37.1%) were also a significant concern for the patients. Most functional and symptom scores showed a reduction at two weeks and improvement at three months. Global health status improved to 68±28.2% (p=0.455), whereas physical functioning improved to 73.8±23.2% (p=0.005) at three months following TACE. After three months following TACE, the QoL scores for the following symptoms improved from baseline: fatigue (30.5±28.2; p=0.012), insomnia (25.9±27.4; p=0.896), and pain (28.5±30.8; p=0.005). High alpha-fetoprotein (AFP), high C-reactive protein (CRP), low albumin, and an increase in Model for End-stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores were found to have a negative impact at three months. Following TACE, 26 (57%), nine (20%), three (7%), and seven (16%) patients had complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), respectively. Quality of life scores showed a positive response at three months in subjects with CR, PR, and SD, while in those with PD, QoL continued to deteriorate over time.
conclusionEffective symptom management, along with the implementation of coping strategies to improve functionality, is crucial when caring for patients who have undergone TACE, particularly during the first two weeks post-procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.